Academic Research

Series editor Andrew Leckey and guest editor Marshall Loeb have scoured the print media and have consulted with editors of major business and general-interest publications and with the deans of several schools of journalism in order to find the 30 best business stories from the past 12 months. Among the articles selected: Ken Auletta on Herb Allen's CEO retreat, from The New Yorker; Diane Brady on Martha Stewart, from Business Week; and Steve Silberman on creating a borderless global cyber-marketplace, from Wired.

Every 69 seconds, someone is diagnosed with Alzheimer's disease. Of the top 10 killers, it is the only disease for which there is no cure or treatment. For most people, there is nothing that they can do to fight back. But one family is doing all they can. The DeMoe family has the most devastating form of the disease that there is: early onset Alzheimer's, an inherited genetic mutation that causes the disease in 100 percent of cases, and has a 50 percent chance of being passed onto the next generation.

At its best, business is both purposeful and profitable, dynamic and gainful, commercial and rewarding. Far from being opposites, good business and good behavior go hand-in-hand, and biblical principles can align with best practices. In Wisdom-Based Business, marketing and supply-chain professor Hannah J. Stolze draws principles from the Bible's wisdom literature and from evidence-based research to create a framework for business that is oriented toward excellence and sustainability.

This is Mary Lasker's story. Americans now recognize the National Institutes of Health as the national treasure that it is, but when she began her crusade, her first challenge was persuading elected leaders and federal officials that the health of the American public was even their problem. Armed with the knowledge she was right, and supported by her husband, the famed ad man Albert Lasker, and close friend Florence Mahoney, she built a coalition of noted physicians and scientists that fundamentally changed how we think about medical research funding.